According to a recent LinkedIn post from Xeltis, the company presented 12‑month EU pivotal trial data for its aXess vascular access device at the CX Symposium 2026. The post highlights performance metrics in hemodialysis access, including 79% secondary patency at 12 months in complex patient groups and a low patency‑related reintervention rate of 1.3 per patient year, alongside reduced infection burden.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that these outcomes, together with prior clinical evidence, supported rapid CE mark approval for aXess, enabling the start of commercialization across Europe. For investors, the move toward European market entry in a hemodialysis segment with significant unmet need could signal an emerging revenue opportunity and strengthen Xeltis’ positioning in the vascular access and broader medtech space.